Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Megan Dehart

Nurse Practitioner, Women's Health Montgomery, OH Nurse Practitioner

NPI 1366778938 CMS profile 10417835

10495 Montgomery Rd Ste 20, Montgomery, OH 45242

Open in the dashboard

General payments

$2,951

165 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Megan Dehart of Montgomery, OH is reported in the CMS Open Payments database as having received $2,951 across 165 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner, Women's Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $413 20
2024 General $507 24
2023 General $524 27
2022 General $693 39
2021 General $815 55

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Megan Dehart
  • Nurse Practitioner, Women's Health median
  • Middle half of Nurse Practitioner, Women's Health
  • National median

In program year 2025, general payments to Megan Dehart were reported at $413. Among 3,829 Nurse Practitioner, Women's Health profiles paid that year, the median was $124 and the middle half received between $42 and $307.

Show as a table
Year Megan Dehart Nurse Practitioner, Women's Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $815 $110 $33–$291 $132
2022 $693 $122 $40–$314 $149
2023 $524 $131 $40–$333 $160
2024 $507 $123 $43–$298 $164
2025 $413 $124 $42–$307 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $361 21 payments
  2. Astellas Pharma US Inc $340 13 payments
  3. TherapeuticsMD, Inc. $303 21 payments
  4. Exeltis, USA Inc. $211 11 payments
  5. Avion Pharmaceuticals $206 17 payments
  6. Pfizer Inc. $196 11 payments
  7. Novo Nordisk Inc $177 10 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $145 8 payments
  9. Lilly USA, LLC $142 9 payments
  10. Mayne Pharma Inc. $110 5 payments
  11. Other $760 39 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,861 164 payments
  2. Education $90 1 payment
Products named General payments · program years 2021–2025
  1. ANNOVERA $303 21 payments
  2. IMVEXXY $303 21 payments
  3. Veozah $250 12 payments
  4. LO LOESTRIN FE $249 15 payments
  5. PREMARIN $215 12 payments
  6. BIJUVA $213 14 payments
  7. Balcoltra $206 17 payments
  8. Wegovy $177 10 payments
  9. TRINTELLIX $145 8 payments
  10. MYFEMBREE $133 8 payments
  11. Other $1,654 91 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

165 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record